Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients

PurposeProgrammed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their synergistic effect is unclear. This study aimed to ev...

Full description

Bibliographic Details
Main Authors: Dengdeng Pan, Dongliang Liu, Lichuan Liang, Tongyi Shen, Chenzhang Shi, Huanlong Qin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
PD-1 inhibitor plus apatinib
advanced colorectal cancer
treatment efficacy
survival outcome
safety profile
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.863392/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.863392/full

Similar Items